Britanin is primarily used in research settings for its potential anti-inflammatory and anticancer properties. It has been studied for its ability to modulate signaling pathways involved in cell proliferation and apoptosis, making it a compound of interest in oncology research. Britanin shows activity in suppressing tumor growth in certain cancer cell lines, particularly in liver and colorectal cancers. It also exhibits immunomodulatory effects, which may contribute to its therapeutic potential in autoimmune diseases. Due to its natural origin and bioactivity, Britanin serves as a lead compound in the development of novel pharmaceutical agents targeting chronic inflammation and malignancies.